Consequently, we chose three candidates from the ±1.6 results for our study: efavirenz, a non-nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection that has previously been analyzed in TNBC43,44; ouabain, an ATPase inhibitor that has been reported as a potential treatment for various types of cancer such as lung45 and breast cancer45,46; and vinburnine (also known as eburnamonine), a vasodilating alkaloid and allosteric modulator of muscarinic acetylcholine receptors47 with antiproliferative effects in leukemia48. The gene discussed is DNAH8; the disease is HIV infectious disease.